The arrival of a new treatment for Alzheimer’s disease has been met with cautious optimism, but a recent recommendation from the Zorginstituut Nederland (Dutch Healthcare Institute) has delivered a blow to patients and advocates. The institute has advised against covering the cost of lecanemab, the active ingredient in the drug Leqembi, through the country’s basic health insurance package, citing limited efficacy. This decision underscores the ongoing challenges in developing and delivering effective treatments for this devastating neurodegenerative disease.
The core concern, according to the Zorginstituut, is that lecanemab demonstrates only a modest benefit for a small subset of individuals in the early stages of Alzheimer’s. Less than 15 percent of patients with beginning Alzheimer’s are even eligible for the treatment, and for those who are, the impact on disease progression is considered too small to justify the financial burden on the healthcare system. Patients continue to experience significant cognitive decline despite treatment, and the drug carries the risk of serious side effects, including brain swelling and bleeding, which can lead to paralysis, speech difficulties, confusion, and, in rare cases, death.
Limited Efficacy and Serious Risks
Lecanemab, developed by Eisai and Biogen, received marketing authorization from the European Commission last year, initially hailed as a potential breakthrough in Alzheimer’s treatment. Yet, the Zorginstituut’s assessment paints a more nuanced picture. The institute’s report, released on February 18, 2026, concludes that the drug’s benefits do not outweigh its risks and costs for the majority of patients. As reported by Zorginstituut Nederland, the limited impact on slowing cognitive decline, coupled with the potential for severe adverse events, led to the negative recommendation.
The drug works by targeting and removing amyloid plaques, abnormal protein deposits that accumulate in the brains of people with Alzheimer’s disease. While the removal of these plaques is thought to be a key step in slowing disease progression, the clinical benefits observed in trials have been modest. NU.nl reports that patients experienced too little noticeable improvement to warrant widespread coverage.
Calls for Patient Choice
Despite the Zorginstituut’s recommendation, Alzheimer Nederland, a patient advocacy organization, is urging the Minister of Health, Welfare and Sport to make Leqembi accessible to a select group of patients, even without full insurance coverage. The organization argues that individuals should have the autonomy to decide whether or not to pursue treatment, even if the benefits are limited.
“There is indeed a modest effect, but it does concern someone’s life,” a spokesperson for Alzheimer Nederland stated, according to RTL Nieuws. “The question of whether you aim for to undergo this treatment is one for the patient in consultation with the treating physician. This deprives a limited group of patients of the opportunity to delay a more severe stage of the disease.”
The organization believes that even a small delay in disease progression could significantly improve quality of life for some individuals and their families. They hope the minister will explore options for making the drug available, even if it means patients must bear some of the cost themselves.
The Broader Context of Alzheimer’s Treatment
The debate surrounding lecanemab highlights the immense challenges in developing effective treatments for Alzheimer’s disease. For decades, researchers have struggled to discover therapies that can halt or even slow the progression of this debilitating condition. While numerous drugs have been tested, many have failed to demonstrate significant clinical benefits.
Lecanemab represents one of the first disease-modifying therapies to show even a modest effect, offering a glimmer of hope for patients and families affected by Alzheimer’s. However, the drug is not a cure, and its benefits are limited. The decision by the Zorginstituut reflects the tricky trade-offs that healthcare systems face when evaluating new and expensive treatments with uncertain benefits.
What’s Next?
The Minister of Health, Welfare and Sport will now review the Zorginstituut’s advice and make a final decision regarding coverage of lecanemab. The minister is expected to announce a decision in the coming weeks. Alzheimer Nederland continues to lobby for patient access, emphasizing the importance of individual choice and the potential benefits, however small, that the drug may offer. The outcome of this decision will likely have significant implications for Alzheimer’s patients and the future of dementia care in the Netherlands.
This situation underscores the urgent need for continued research into Alzheimer’s disease and the development of more effective treatments. Until a cure is found, patients and families will continue to grapple with the challenges of managing this devastating illness.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. We see essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
What are your thoughts on the accessibility of new Alzheimer’s treatments? Share your perspective in the comments below, and please share this article with anyone who may find it helpful.
